PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1428490
PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1428490
India Cancer Immunotherapy Market, By Type, By Application, By End User (Hospitals, Cancer Research Centers, Clinics), By Region, Trend Analysis, Competitive Landscape & Forecast, 2019-2030
India Cancer Immunotherapy Market Size Expands at Significant CAGR of 6.39% During 2024-2030, Reaching USD 102.11 Billion by 2030
India Cancer Immunotherapy Market is flourishing because of the increasing prevalence of cancer, government initiatives & funding, and rising healthcare expenditure.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the India Cancer Immunotherapy Market size at USD 98.37 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects the India Cancer Immunotherapy Market size to grow at a significant CAGR of 6.39% reaching a value of USD 102.11 billion by 2030. As per the Indian Council of Medical Research - National Cancer Registry Programme (ICMR-NCRP), the estimated number of incidences of cancer cases in the country in 2022 was 14,61,427. Supportive government initiatives and funding for cancer research and treatment play a pivotal role. Investments in healthcare infrastructure and programs that promote immunotherapy adoption contribute to market growth. The Central Government has implemented the Strengthening of Tertiary Cancer Care Centres Facilities Scheme to improve cancer treatment facilities. The plan has approved 19 state cancer institutes (SCIs) and 20 tertiary care cancer centres (TCCCs). Increased healthcare spending, both by the government and individuals, fuels the adoption of advanced cancer treatments. This includes immunotherapies that offer promising outcomes in combating cancer
Opportunity: Advancements in Research and Development
Ongoing research and development activities in cancer immunotherapy provide prospects for the introduction of novel and more effective immunotherapeutic drugs. This may improve therapy options and outcomes for cancer patients in India. Novel therapy techniques, such as immune checkpoint inhibitors and adoptive cell treatments, are emerging as viable options for cancer patients in India. The Central Drugs Standard Control Organisation (CDSCO) has approved CAR-T (Chimeric Antigen Receptor-T) cell therapy, a ground-breaking treatment for relapsed/refractory (r/r) B-cell lymphomas and leukaemia, paving the way for the commercial launch of indigenous NexCAR19 in the country. ImmunoACT, an IIT Bombay incubated firm, developed the treatment.
Impact of Geopolitical Tension on India Cancer Immunotherapy Market
Geopolitical conflicts may cause interruptions in the pharmaceutical supply chain, compromising the availability of critical chemicals and medications. Political uncertainty may cause changes to regulatory frameworks, influencing medication approval processes and market access for immunotherapeutic treatments. Geopolitical instability may have an impact on foreign healthcare investments and funding, as well as cancer immunotherapy research and development initiatives. Political tensions can cause changes in trade policies, influencing the import and export of pharmaceutical products and potentially limiting access to cancer immunotherapies. Collaborations for multinational clinical trials, a critical part of drug development, may confront problems due to geopolitical tensions, affecting the progression of new cancer immunotherapy treatments.
India Cancer Immunotherapy Market - By End User
Based on end user, the India cancer immunotherapy market is segmented into hospitals, cancer research centers, and clinics. The hospital segment dominates the Indian cancer immunotherapy market. This is attributable to a number of variables, including a rise in the number of hospital admissions for cancer treatment, expanded hospital penetration across the country, and a greater preference for hospital care. Furthermore, the growing number of government and private hospitals, as well as the increasing use of cutting-edge technologies, add to hospitals' dominance in the cancer immunotherapy industry. Hospitals have the infrastructure and resources necessary to successfully deliver and monitor immunotherapy therapies.
India Cancer Immunotherapy Market - By Region
Regionally, the India Cancer Immunotherapy Market is segmented as North India, South India, East India, and West India. North India is expected to grow during the forecast period. North India, particularly Delhi and surrounding regions, boasts advanced healthcare infrastructure with leading hospitals and research centers. This facilitates the adoption and accessibility of cancer immunotherapy treatments. North India attracts a significant number of medical tourists seeking specialized cancer treatments, including immunotherapy. The presence of renowned healthcare institutions contributes to the region's dominance.
Competitive Landscape
Major players operating in the India Cancer Immunotherapy Market include Astellas Pharma Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Lilly, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Gilead Sciences, Inc, GSK plc, Johnson & Johnson, Sanofi. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of India Cancer Immunotherapy Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in India Cancer Immunotherapy Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
Table of Contents
1. Research Framework
- 1.1. Research Objective
- 1.2. Product Overview
- 1.3. Market Segmentation
2. Executive Summary
3. India Cancer Immunotherapy Market Insights
- 3.1. Industry Value Chain Analysis
- 3.2. DROC Analysis
- 3.2.1. Growth Drivers
- 3.2.1.1. Increasing cancer incidence
- 3.2.1.2. Government initiatives and funding
- 3.2.1.3. Collaborations and partnerships
- 3.2.2. Restraints
- 3.2.2.1. High treatment costs
- 3.2.2.2. Stringent regulatory requirements and approval processes
- 3.2.2.3. Side effects and safety concerns
- 3.2.3. Opportunities
- 3.2.3.1. Advancements in research and development
- 3.2.3.2. Patient awareness and education
- 3.2.4. Challenges
- 3.2.4.1. Infrastructure and expertise
- 3.2.4.2. Resistance mechanisms
- 3.2.1. Growth Drivers
- 3.3. Technology Advancements/Recent Developments
- 3.4. Regulatory Framework
- 3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry
4. India Cancer Immunotherapy Market: Marketing Strategies
5. India Cancer Immunotherapy Market Overview
- 5.1. Market Size & Forecast, 2019-2030
- 5.1.1. By Value (USD Billion)
- 5.2. Market Share & Forecast
- 5.2.1. By Type
- 5.2.1.1. Monoclonal Antibodies
- 5.2.1.2. Cancer Vaccines
- 5.2.1.3. Checkpoint Inhibitors
- 5.2.1.4. Immunomodulators
- 5.2.2. By Application
- 5.2.2.1. Lung Cancer
- 5.2.2.2. Breast Cancer
- 5.2.2.3. Colorectal Cancer
- 5.2.2.4. Melanoma
- 5.2.2.5. Prostate Cancer
- 5.2.2.6. Head and Neck Cancer
- 5.2.2.7. Others
- 5.2.3. By End User
- 5.2.3.1. Hospitals
- 5.2.3.2. Cancer Research Centers
- 5.2.3.3. Clinics
- 5.2.4. By Region
- 5.2.4.1. North India
- 5.2.4.2. South India
- 5.2.4.3. East India
- 5.2.4.4. West India
- 5.2.1. By Type
6. North India Cancer Immunotherapy Market
- 6.1. Market Size & Forecast, 2019-2030
- 6.1.1. By Value (USD Billion)
- 6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Application
- 6.2.3. By End User
7. South India Cancer Immunotherapy Market
- 7.1. Market Size & Forecast, 2019-2030
- 7.2. By Value (USD Billion)
- 7.3. Market Share & Forecast
- 7.3.1. By Type
- 7.3.2. By Application
- 7.3.3. By End User
8. East India Cancer Immunotherapy Market
- 8.1. Market Size & Forecast, 2019-2030
- 8.2. By Value (USD Billion)
- 8.3. Market Share & Forecast
- 8.3.1. By Type
- 8.3.2. By Application
- 8.3.3. By End User
9. West India Cancer Immunotherapy Market
- 9.1. Market Size & Forecast, 2019-2030
- 9.1.1. By Value (USD Billion)
- 9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Application
- 9.2.3. By End User
10. Competitive Landscape
- 10.1. List of Key Players and Their Offerings
- 10.2. India Cancer Immunotherapy Company Market Share Analysis, 2023
- 10.3. Competitive Benchmarking, By Operating Parameters
- 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Geopolitical Tension in India Cancer Immunotherapy Market
12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
- 12.1. Astellas Pharma Inc.
- 12.2. AstraZeneca
- 12.3. Bayer AG
- 12.4. Bristol-Myers Squibb
- 12.5. Lilly
- 12.6. F. Hoffmann-La Roche Ltd
- 12.7. Merck & Co., Inc.
- 12.8. Novartis AG
- 12.9. Pfizer Inc.
- 12.10. Gilead Sciences, Inc
- 12.11. GSK plc
- 12.12. Johnson & Johnson
- 12.13. Sanofi
- 12.14. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology
- 14.1. Qualitative Research
- 14.1.1. Primary & Secondary Research
- 14.2. Quantitative Research
- 14.3. Market Breakdown & Data Triangulation
- 14.3.1. Secondary Research
- 14.3.2. Primary Research
- 14.4. Breakdown of Primary Research Respondents, By Region
- 14.5. Assumptions & Limitations
*Financial information of case of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable
List of Figures
- Figure 1 India Cancer Immunotherapy Segmentation
- Figure 2 India Cancer Immunotherapy Market Value Chain Analysis
- Figure 3 Company Market Share Analysis, 2023
- Figure 4 India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Figure 5 India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Figure 6 India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Figure 7 India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
- Figure 8 India Cancer Immunotherapy Market Share, By Region, By Value, 2019-2030
- Figure 9 North India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Figure 10 North India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Figure 11 North India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Figure 12 North India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
- Figure 13 South India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Figure 14 South India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Figure 15 South India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Figure 16 South India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
- Figure 17 East India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Figure 18 East India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Figure 19 East India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Figure 20 East India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
- Figure 21 South India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Figure 22 South India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Figure 23 South India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Figure 24 South India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
- Figure 25 West India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Figure 26 West India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Figure 27 West India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Figure 28 West India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
List of Tables
- Table 1 India Cancer Immunotherapy Segmentation
- Table 2 India Cancer Immunotherapy Market Value Chain Analysis
- Table 3 Company Market Size Analysis, 2023
- Table 4 India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Table 5 India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Table 6 India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Table 7 India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
- Table 8 India Cancer Immunotherapy Market Share, By Region, By Value, 2019-2030
- Table 9 North India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Table 10 North India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Table 11 North India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Table 12 North India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
- Table 13 South India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Table 14 South India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Table 15 South India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Table 16 South India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
- Table 17 East India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Table 18 East India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Table 19 East India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Table 20 East India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
- Table 21 South India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Table 22 South India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Table 23 South India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Table 24 South India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
- Table 25 West India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030
- Table 26 West India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030
- Table 27 West India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030
- Table 28 West India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030
- Table 29 Astellas Pharma Inc. Company Overview
- Table 30 Astellas Pharma Inc. Financial Overview
- Table 31 AstraZeneca Company Overview
- Table 32 AstraZeneca Financial Overview
- Table 33 Bayer AG Company Overview
- Table 34 Bayer AG Financial Overview
- Table 35 Bristol-Myers Squibb Company Overview
- Table 36 Bristol-Myers Squibb Financial Overview
- Table 37 Lilly Company Overview
- Table 38 Lilly Financial Overview
- Table 39 F. Hoffmann-La Roche Ltd Company Overview
- Table 40 F. Hoffmann-La Roche Ltd Financial Overview
- Table 41 Merck & Co., Inc. Company Overview
- Table 42 Merck & Co., Inc. Financial Overview
- Table 43 Novartis AG Company Overview
- Table 44 Novartis AG Financial Overview
- Table 45 Pfizer Inc. Company Overview
- Table 46 Pfizer Inc. Financial Overview
- Table 47 Gilead Sciences, Inc Company Overview
- Table 48 Gilead Sciences, Inc Financial Overview
- Table 49 GSK plc Company Overview
- Table 50 GSK plc Financial Overview
- Table 51 Johnson & Johnson Company Overview
- Table 52 Johnson & Johnson Financial Overview
- Table 53 Sanofi Company Overview
- Table 54 Sanofi Financial Overview
